Integra LifeSciences Announces Launch of the Integra(R) IPP-ON(R) PIP Fusion System for Extremity Reconstruction
PLAINSBORO, N.J., June 20, 2012 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (Nasdaq:IART) today announced the introduction of Integra® IPP-ON® PIP Fusion System, for fixation of proximal interphalangeal (PIP) joint arthrodesis. It is indicated for use in the lesser toes for rigid or semi-rigid hammertoe deformity, revision of failed arthroplasty or arthrodesis, and second toe shortening. The Integra® IPP-ON® PIP Fusion System has received 510(k) clearance from the United States Food & Drug Administration (FDA), and will be featured at the American Orthopaedic Foot & Ankle Society 2012 Annual Meeting on June 20-23, 2012 in San Diego, California.
"Integra® IPP-ON® PIP Fusion System offers surgeons a straightforward, one-piece alternative to hammertoe fixation. Unlike some similar products, our device is not temperature sensitive and has no handling or storage requirements. This is an excellent feature, since it is ready for use whenever the surgeon needs it," said Bill Weber, Vice President and General Manager, Integra Extremity Reconstruction. "This system is a valuable addition to our already extensive portfolio of Forefoot Extremity products."
The Integra® IPP-ON® PIP Fusion System is a one-piece, stainless steel interphalangeal fusion device that is available in two sizes, to accommodate varying patient anatomy. The device is anatomically adaptive by offering both cortical and cancellous fixation.
Hammertoe is a deformity that occurs when there is a shortening of the tendon that controls toe movement. The tendon shortening causes the middle joint of the toe to be bent upward and the most distal joint downward.
The Integra® IPP-ON® PIP Fusion System is distributed through Integra's Extremity Reconstruction sales organization, which focuses on lower extremity fixation, upper extremity fixation, tendon protection, peripheral nerve repair/protection and wound repair.
Integra LifeSciences, a world leader in medical devices, is dedicated to limiting uncertainty for surgeons, so they can concentrate on providing the best patient care. Integra offers innovative solutions in orthopedics, neurosurgery, spine, reconstructive and general surgery. For more information, please visit www.integralife.com.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include, but are not limited to, statements concerning the products and services provided by Integra. Such forward looking statements involve risks and uncertainties that could cause actual results to differ materially from predicted or expected results. Among other things, the willingness of surgical professionals to use Integra products may affect the prospects for their use in surgical procedures. In addition, the economic, competitive, governmental, technological and other factors, identified under the heading "Risk Factors" included in Item IA of Integra's Annual Report on Form 10-K for the year ended December 31, 2011 and information contained in subsequent filings with the Securities and Exchange Commission could affect actual results.
CONTACT: Integra LifeSciences Holdings Corporation
Gianna Sabella
Director, Corporate Communications
(609) 936-2389
gianna.sabella@integralife.com